Drug Trial Radar · NCT03625622
Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
210
Actual
Start
Apr 1, 2019
Primary completion
Dec 21, 2020
Study completion Jun 28, 2021
Sponsor
- Lead sponsor
- AriBio Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A double-blinded, randomized, placebo-controlled study will be performed to evaluate the efficacy and safety of treating AR1001 in patients with mild to moderate Alzheimer's disease for 26 weeks. An optional 26 week extension phase will be available to participants who successfully complete the original phase of the study.
Conditions
- Mild to Moderate Alzheimer's Disease
Interventions
AR1001 10mgDrug
AR1001 Active Oral Tablet 10mg
PlaceboDrug
Placebo Oral Tablet
AR1001 30mgDrug
AR1001 Active Oral Tablet 30mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog 13)Time frame: Baseline to Week 26
- Change From Baseline in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)Time frame: Baseline to Week 26
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Advanced Clinical Research, Inc.
Banning, California
Northern California Research
Sacramento, California
Syrentis Clinical Research
Santa Ana, California
Meridien Research
Lakeland, Florida
Meridien - Maitland
Maitland, Florida
The Neurology Research Group
Miami, Florida
Accelerated Enrollment Solutions (AES)
Orlando, Florida
IMIC, Inc
Palmetto Bay, Florida
Meridien Research - Spring Hill
Spring Hill, Florida
Meridien Research - St Petersburg
St. Petersburg, Florida
Meridien Research - Tampa
Tampa, Florida
NeuroStudies, LLC
Decatur, Georgia
Advanced Clinical Research
Meridian, Idaho
Wake Research - CRCNV
Las Vegas, Nevada
Rapid Medical Research
Beachwood, Ohio
Lynn Health Science Institute
Oklahoma City, Oklahoma
Palmetto Clinical Research
Summerville, South Carolina
Advanced Clinical Research - Cedar Park
Cedar Park, Texas
FMC Science
Lampasas, Texas
Advanced Clinical Research, Inc.
West Jordan, Utah
Kingfisher Cooperative, LLC
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.